GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Emergent BioSolutions Inc (STU:ER4) » Definitions » Shiller PE Ratio

Emergent BioSolutions (STU:ER4) Shiller PE Ratio : 39.95 (As of May. 13, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Emergent BioSolutions Shiller PE Ratio?

As of today (2024-05-13), Emergent BioSolutions's current share price is €3.995. Emergent BioSolutions's E10 for the quarter that ended in Mar. 2024 was €0.10. Emergent BioSolutions's Shiller PE Ratio for today is 39.95.

The historical rank and industry rank for Emergent BioSolutions's Shiller PE Ratio or its related term are showing as below:

STU:ER4' s Shiller PE Ratio Range Over the Past 10 Years
Min: 4.53   Med: 32.87   Max: 113
Current: 38.32

During the past years, Emergent BioSolutions's highest Shiller PE Ratio was 113.00. The lowest was 4.53. And the median was 32.87.

STU:ER4's Shiller PE Ratio is ranked worse than
71.62% of 532 companies
in the Drug Manufacturers industry
Industry Median: 25.645 vs STU:ER4: 38.32

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Emergent BioSolutions's adjusted earnings per share data for the three months ended in Mar. 2024 was €0.156. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is €0.10 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Emergent BioSolutions Shiller PE Ratio Historical Data

The historical data trend for Emergent BioSolutions's Shiller PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Emergent BioSolutions Shiller PE Ratio Chart

Emergent BioSolutions Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Shiller PE Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 47.36 58.45 21.77 7.51 95.50

Emergent BioSolutions Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Shiller PE Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.25 10.26 20.28 95.50 22.28

Competitive Comparison of Emergent BioSolutions's Shiller PE Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Emergent BioSolutions's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Emergent BioSolutions's Shiller PE Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Emergent BioSolutions's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Emergent BioSolutions's Shiller PE Ratio falls into.



Emergent BioSolutions Shiller PE Ratio Calculation

For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Emergent BioSolutions's Shiller PE Ratio for today is calculated as

Shiller PE Ratio=Share Price/ E10
=3.995/0.1
=39.95

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emergent BioSolutions's E10 for the quarter that ended in Mar. 2024 is calculated as:

For example, Emergent BioSolutions's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS=Earnings per Share (Diluted)/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.156/129.4194*129.4194
=0.156

Current CPI (Mar. 2024) = 129.4194.

Emergent BioSolutions Quarterly Data

Earnings per Share (Diluted) CPI Adj_EPS
201406 0.096 100.560 0.124
201409 0.380 100.428 0.490
201412 0.535 99.070 0.699
201503 -0.527 99.621 -0.685
201506 0.285 100.684 0.366
201509 0.704 100.392 0.908
201512 0.652 99.792 0.846
201603 0.090 100.470 0.116
201606 -0.240 101.688 -0.305
201609 0.401 101.861 0.509
201612 0.635 101.863 0.807
201703 0.215 102.862 0.271
201706 0.098 103.349 0.123
201709 0.571 104.136 0.710
201712 0.566 104.011 0.704
201803 -0.081 105.290 -0.100
201806 0.839 106.317 1.021
201809 0.351 106.507 0.427
201812 -0.062 105.998 -0.076
201903 -0.451 107.251 -0.544
201906 -0.159 108.070 -0.190
201909 0.754 108.329 0.901
201912 0.801 108.420 0.956
202003 -0.217 108.902 -0.258
202006 1.536 108.767 1.828
202009 0.620 109.815 0.731
202012 2.828 109.897 3.330
202103 1.075 111.754 1.245
202106 0.075 114.631 0.085
202109 -0.519 115.734 -0.580
202112 3.098 117.630 3.409
202203 -0.064 121.301 -0.068
202206 -1.069 125.017 -1.107
202209 -1.768 125.227 -1.827
202212 -1.661 125.222 -1.717
202303 -3.465 127.348 -3.521
202306 -4.753 128.729 -4.779
202309 -4.760 129.860 -4.744
202312 -0.807 129.419 -0.807
202403 0.156 129.419 0.156

Add all the adjusted EPS together and divide 10 will get our E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Emergent BioSolutions  (STU:ER4) Shiller PE Ratio Explanation

Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.

Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.


Be Aware

Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.


Emergent BioSolutions Shiller PE Ratio Related Terms

Thank you for viewing the detailed overview of Emergent BioSolutions's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Emergent BioSolutions (STU:ER4) Business Description

Traded in Other Exchanges
Address
400 Professional Drive, Suite 400, Gaithersburg, MD, USA, 20879
Emergent BioSolutions Inc offers public health products to the government and healthcare providers. The company has four main units: vaccines, which produces specialty vaccines for public health threats; devices, such as nasal sprays, skin lotions, and injections; therapeutics, which includes antibody-based treatments; and contract development and manufacturing, which brings treatments to market through collaboration with the pharmaceutical and biotechnology industries and the United States government. Most revenue comes from U.S. government purchases of vaccines, devices, and therapeutic products. The company operates in two reportable segments; the Products Segment and the Services Segment.

Emergent BioSolutions (STU:ER4) Headlines

No Headlines